Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX)
|
Add to portfolio |
|
|
|
| Price: |
$0.02
| | Metrics |
| OS: |
9.25
|
M
| |
-40658
|
% ROE
|
| Market cap: |
$212.9
|
k
| |
|
|
|
Net debt:
|
$1.73
|
M
| |
|
|
|
EV:
|
$1.95
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($9.7)
|
M
| |
|
|
|
EBIT
|
($9.8)
|
M
| |
|
|
| EPS |
($3.45)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 0.0 | 0.1 | 1.3 | 0.3 | 0.4 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -100.0% | -88.3% | 303.3% | -14.2% | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.1 | 1.3 | 0.3 | 0.4 | 0.0 | 0.0 | 0.0 |
| Gross margin | | 100.0% | 100.0% | 100.0% | 100.0% | | | |
| Selling, general and administrative | | | | | | | | 26.1 |
| Research and development | 7.5 | 7.8 | 9.6 | 3.5 | 3.0 | 3.5 | 5.6 | |
| General and administrative | 10.5 | 9.0 | 9.8 | 5.2 | 1.4 | 4.5 | 6.5 | |
| EBIT | -18.1 | -16.7 | -18.1 | -8.4 | -4.0 | -8.0 | -12.1 | 0.0 |
| EBIT margin | | -11254.8% | -1430.5% | -2671.4% | -1103.6% | | | |
| Pre-tax income | -19.0 | -17.7 | -18.1 | -7.9 | -4.0 | -8.0 | -12.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | -32.8 | -17.7 | -36.1 | -10.6 | -4.7 | -8.0 | -12.0 | 0.0 |
| Net margin | | -11928.4% | -2845.3% | -3366.8% | -1292.9% | | | |
| |
| Diluted EPS | ($8.56) | ($10.91) | ($13.44) | ($9.51) | ($20.55) | ($3.64) | ($6.69) | $0.00 |
| Shares outstanding (diluted) | 3.8 | 1.6 | 2.7 | 1.1 | 0.2 | 2.2 | 1.8 | 1.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|